RxDoctor Payments Data

Tatjana Sljapic, MD

Clinical Cardiac Electrophysiology · Brick, NJNPI 1255385845

Payments from drug & device makers

$15,001in general payments, 2019–2025

Across 271 payments — averaging $55.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$7K
  • Boston Scientific$3K
  • Biotronik Inc.$2K
  • Abbott$838
  • Sanofi-aventis U.S. LLC$443
  • Novartis$244
  • plus $1K from 24 others

What the payments were for

  • Speaking & faculty fees$4003%
  • Grants$2942%
  • Travel & lodging$6,40543%
  • Food & beverage$7,50550%
  • Education$3973%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,001 in reported general payments places this provider in the 40th percentile of 102 clinical cardiac electrophysiology providers in New Jersey.

See all clinical cardiac electrophysiology providers in New Jersey

Medicare billing

Part B allowed, 2024
$476,050
Medicare patients
901
Services billed
2,721

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis13$271,387
EliquisApixaban181$173,647
XareltoRivaroxaban31$42,676
EntrestoSacubitril/Valsartan27$24,780
FarxigaDapagliflozin Propanediol19$24,215
BrilintaTicagrelor27$19,529
Metoprolol Succinate145$2,711
Amiodarone Hcl71$2,191
Diltiazem 24hr Er (Cd)Diltiazem Hcl16$1,441
Bisoprolol Fumarate52$1,310
Flecainide Acetate36$1,300
Atorvastatin Calcium53$770
Rosuvastatin Calcium53$695
Potassium Chloride17$618
Amlodipine Besylate54$612

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$210$445,034194 claims
AstraZenecaFarxiga, Brilinta$20$43,74446 claims
Johnson & JohnsonXarelto$71$42,67631 claims
NovartisEntresto$244$24,78027 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 102 clinical cardiac electrophysiology providers in New Jersey.

Other clinical cardiac electrophysiology in Brick

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →